ETXP.F Stock Overview
Engages in drug discovery research activities in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
e-therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.13 |
| 52 Week High | US$0.22 |
| 52 Week Low | US$0.13 |
| Beta | 0.48 |
| 1 Month Change | 0% |
| 3 Month Change | -7.14% |
| 1 Year Change | -55.17% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -43.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| ETXP.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -3.8% | -2.7% |
| 1Y | -55.2% | -2.6% | 23.4% |
Return vs Industry: ETXP.F underperformed the US Biotechs industry which returned 13.7% over the past year.
Return vs Market: ETXP.F underperformed the US Market which returned 22.3% over the past year.
Price Volatility
| ETXP.F volatility | |
|---|---|
| ETXP.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ETXP.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ETXP.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 35 | Ahmad Mortazavi | www.etherapeutics.co.uk |
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. The company offers HepNet, a hepatocyte-focused computational platform that enables identification of novel gene targets, improves drug design, and increases automation; and GalOmic, RNA interference (RNAi) platform that generates potent and safe GalNAc-siRNA therapeutics to selectively silence novel disease-associated genes in hepatocytes. Its preclinical products are ETX-312 to treat metabolic dysfunction-associated steatohepatitis; and ETX-407 for the treatment of dry age-related macular degeneration.
e-therapeutics plc Fundamentals Summary
| ETXP.F fundamental statistics | |
|---|---|
| Market cap | US$75.96m |
| Earnings (TTM) | -US$14.50m |
| Revenue (TTM) | US$412.94k |
184.0x
P/S Ratio-5.2x
P/E RatioIs ETXP.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ETXP.F income statement (TTM) | |
|---|---|
| Revenue | UK£318.00k |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£318.00k |
| Other Expenses | UK£11.48m |
| Earnings | -UK£11.17m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.019 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,511.32% |
| Debt/Equity Ratio | 0% |
How did ETXP.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/07/14 00:21 |
| End of Day Share Price | 2024/04/16 00:00 |
| Earnings | 2024/01/31 |
| Annual Earnings | 2024/01/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
e-therapeutics plc is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Philip Morrish | Growth Equities & Company Research |
| Paul Cuddon | Numis Securities Ltd. |
| Savvas Neophitou | Panmure Liberum Historic (Panmure Gordon) |